

Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

MYND Life Sciences, Inc. (the "Company")
719 Finns Road
Kelowna, BC V1X 5B7

Item 2 Date of Material Change

March 9, 2022

Item 3 News Release

A news release relating to the material changes described herein was disseminated via Newsfile on March 9, 2022.

Item 4 Summary of Material Change

The Company's Chief Financial Officer, Paul Ciullo, has resigned from the Company effective February 28, 2022.

Item 5 Full Description of Material Change

Full Description of Material Change

See Appendix "A".

Disclosure for Restructuring Transactions

N/A

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

N/A

Item 7 Omitted Information

N/A

Item 8 Executive Officer

The following senior officer of the Issuer is knowledgeable about the material change and the report and may be contacted by the Commission as follows:

Dr. Lyle Oberg
Tel: 1-780 965-0122

Item 9 Date of Report

March 9, 2022

Appendix “A”



MYND Life Sciences Inc. Announces the Recruitment of a Senior Operations and Research Manager

VANCOUVER, BRITISH COLUMBIA, March 9, 2022 – **MYND Life Sciences Inc.** ("MYND" or "the Company") (CSE: MYND) (OTC: MYNDF) announces the hiring of a Senior Operations and Research Manager and the resignation of a company officer.

MYND is pleased to announce the hiring of Dr. Chaahat S.B Singh as the Company's Senior Operations and Research Manager. In 2019, Dr. Singh was awarded a PhD in Medical Genetics focusing on Central Nervous System (CNS) disorders at the University of British Columbia. She has previously worked at Panacea Biotec Ltd. on the development of a Hepatitis B vaccine. Later Dr. Singh worked at the Institute of Microbial Technology, India, investigating the mechanisms underlying Drug-resistance in Tuberculosis. During her PhD, under the supervision of MYND's Chief Science Officer, Dr. Wilf Jefferies, Dr. Singh studied vascular dysfunction associated with Alzheimer's disease (AD), establishing an alternative mechanism to explain the blood-brain barrier disruption and disease pathology. Most recently, Dr. Singh co-authored the eBioMedicine-The Lancet publication entitled "*Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics,*" where Dr. Singh and colleagues explored the potential of anti-angiogenic small molecules used in cancer therapy as novel and promising therapeutics for AD.

Chief Science Officer, Dr. Wilf Jefferies, stated that, "Dr. Singh's skills are in organizing and managing complex research and development projects and her scientific experience and extensive research capabilities will be extremely valuable to fulfilling the immense promise of the innovations being developed at MYND".

DEPARTURE OF AN OFFICER OF THE COMPANY

The Company's Board of Directors has accepted the resignation of Chief Financial Officer Mr. Paul Cuillo, with effect from February 28, 2022. The Board would like to express its appreciation to Mr. Cuillo for his efforts, contributions, and support with the transition.

Mr. Cuillo's responsibilities will be assumed by our current Senior Controller, and interim Chief Financial Officer, Mr. Lih-Ming Tam. Mr. Tam has worked directly with Mr. Cuillo since MYND's inception. Over the past 30 years, Mr. Tam has established a proven track record in start-up enterprises and established public corporations as a sophisticated financial expert. Mr. Tam is the Chief Financial Officer and Co-Founder of Green Light Innovation Partners and specializes in providing technical, compliance and project funding, management and oversight for Scientific Research and Experimental Development (SRED) programs. Mr. Tam's financial experience and diverse capabilities will undoubtedly assist in advancing MYND's growth.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuropharmaceutical and novel psilocybin drug development, diagnostics and vaccines. **MYND** is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of Psilocybins for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.

For more information and to subscribe to MYND's mailing list, please visit <https://myndsciences.com/contact/>.

CONTACT INFORMATION

Dr. Lyle Oberg, MD, CEO

Email: ir@myndsciences.com

Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.